Skip to main content

Effects of Cognitive-Behavioral Treatment in Children With Affective Dysregulation (ADOPT-Treatment): A Randomized Controlled Trial

In brief

CBT did not outperform usual care for childhood affective dysregulation

In a randomized trial of 159 children aged 8 to 12, a 24-session cognitive-behavioral program did not reduce affective dysregulation more than high-quality usual care; both groups improved modestly over time. The program was feasible and well-received, but whether children with more severe symptoms benefit more remains uncertain, and the trial was not powered to detect small effects.

Journal
Journal of the American Academy of Child and Adolescent Psychiatry (Q1)
Published
12 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Anne-Katrin Treier, Kristina Butz, Franziska Frenk, Claudia Ginsberg, Carolina Goldbeck, Michaela Junghänel, et al.
PMID
43020425
DOI
10.1016/j.jaac.2026.11.001

Why clinicians should know about it

  • Picked for Pediatrics and Child Health (top studies of the week, 15 November 2026): Randomized trial of treatment for childhood affective dysregulation

Abstract

OBJECTIVE: Affective dysregulation (AD) in childhood is characterized by heightened reactivity to emotional stimuli and impairments across multiple domains. Evidence on the efficacy of psychosocial interventions specifically tailored to AD is scarce. METHOD: In this multicenter randomized controlled trial, 159 children aged 8-12 years with AD were randomized to either a modular cognitive-behavioral intervention (THOPAS; 24 sessions) or treatment as usual (TAU). Primary outcome was clinician-rated AD symptom severity (blinded and composite), and secondary outcomes were functional impairment, co-occurring conditions, emotion regulation, and parenting. Assessments were conducted at baseline, post-intervention, and 32-week follow-up. The analyses followed modified intention-to-treat and per-protocol principles. RESULTS: No between-group differences emerged for the primary outcome, and only isolated effects were found for secondary outcomes. Both THOPAS and TAU showed small-to-moderate improvements over time. Exploratory subgroup analyses suggested that children with higher baseline symptom severity may have benefited more from THOPAS. Feasibility indicators suggested high therapist fidelity, strong parental engagement, high satisfaction, and high safety for THOPAS. CONCLUSION: The trial found no overall superiority of THOPAS over high-quality TAU. While THOPAS was feasible and well-received, the study was not powered to detect small effects. Future research should incorporate both standardized and individualized outcome measures, refine baseline severity thresholds, and examine the long-term stability of treatment effects. CLINICAL TRIAL REGISTRATION INFORMATION: Efficacy of a Personalized Modular Outpatient Treatment of Affective Dysregulation and Coexisting Conditions in Children (ADOPT Treatment); https://drks.de/search/en/trial/DRKS00013317.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.